Prop. 71's fine print contains surprises: Tightly written law leaves little room for oversight or changes
By Bernadette Tansey,
San Francisco Chronicle
| 12. 08. 2004
The $3 billion stem cell initiative that passed overwhelmingly last month holds surprises for voters who didn't read it -- starting with a provision that the research money doesn't have to be spent on stem cell studies.
It's also not the case, contrary to campaign pitches for Proposition 71, that the $3 billion raised from state bonds won't cost the state anything for the first five years. Interest payments will begin immediately, paid out of the bond money itself -- meaning that tens to hundreds of millions of "research" dollars must be used to pay debt service.
And as lawmakers and critics have learned, if they find fault with the ballot initiative, changing it could be tough. Under the proposition's terms, the state Legislature can't modify the law for three years. Even then, it can do so only by a 70 percent vote of both houses and with the governor's approval.
Some laws are like a car patched together from spare parts, but the California Stem Cell Research and Cures Initiative is built like a tank. Lawyers involved in...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...